Saturday 17 October 2026
Export MRVI’s income statement to Excel — free account
Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.79
0.28
−3.96%
Follow MRVI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
4.42 | 2.02 | 2.53 | 2.16 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
231.34 | 47.82 | (20.61) | (27.41) | |
P/B ratio |
2.60 | 1.12 | 1.26 | 0.96 | |
Price to Tangible BV |
10.52 | 4.37 | 5.11 | 3.56 | |
EV/Sales |
4.93 | 2.54 | 3.09 | 2.57 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(40.78) | (13.14) | (9.97) | (10.01) | |
EV/FCF |
(28.74) | (9.87) | (8.12) | (7.46) | |
Quick Ratio |
2.63 | 4.68 | 5.40 | 4.32 | |
Current Ratio |
4.05 | 5.91 | 6.60 | 5.29 | |
Net Debt/EBITDA |
(63.38) | 9.70 | (1.21) | 4.29 | |
Debt/Assets |
29.27% | 37.98% | 41.78% | 38.06% | |
Debt/Equity |
0.50 | 0.73 | 0.86 | 0.75 | |
Asset Turnover |
0.28 | 0.24 | 0.21 | 0.18 | |
Operating CF/Net income |
(0.32) | (2.32) | 0.64 | 0.59 | |
Capex/Depreciation |
(0.03) | (0.34) | 0.08 | (0.06) | |
Interest Coverage |
(3.14) | (0.38) | (8.97) | (6.00) | |
Research and Development Expense of Revenue |
7.20% | 5.91% | 7.60% | 9.23% | |
Selling, General and Administrative Expense of Revenue |
62.34% | 44.19% | 63.05% | 85.03% | |
Intangible Assets out of Total Assets |
0.44 | 0.38 | 0.36 | 0.37 | |
Share Based Compensation of Revenue |
19.84% | 10.24% | 7.87% | 21.75% | |
Graham Net Nets |
(0.10) | (0.22) | (0.22) | (0.22) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.33%) | (25.09%) | (27.69%) | (29.27%) | |
Free Cash Flow Yield |
(3.88%) | (12.69%) | (15.07%) | (15.97%) | |
Revenue per Share |
0.35 | 0.45 | 0.35 | 0.29 | |
Operating CF per Share |
0.03 | 0.06 | (0.16) | (0.10) | |
Capex per Share |
0.00 | (0.03) | (0.01) | (0.03) | |
Free Cash Flow per Share |
0.02 | 0.03 | (0.17) | (0.13) | |
Cash per Share |
0.47 | 1.13 | 1.50 | 1.68 | |
Shareholders Equity per Share |
2.40 | 2.52 | 2.58 | 2.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.40 | 2.52 | 2.58 | 2.98 | |
Free Cash Flow |
3.62 | 4.23 | (24.88) | (18.81) | |
Working Capital |
117.24 | 209.11 | 251.33 | 264.29 | |
Capital Expenditures |
(0.37) | (4.44) | (2.11) | (3.66) | |
Net Current Asset Value |
(92.50) | (92.40) | (101.61) | (91.46) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.07 | 0.04 | 0.09 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
29.51 | 30.95 | 32.01 | 25.71 | |
Average Payables |
9.33 | 9.03 | 7.43 | 8.75 | |
Average Inventory |
43.95 | 45.12 | 45.29 | 47.87 | |
Average Assets |
750.36 | 836.48 | 889.41 | 1,063.70 | |
Average Common Equity |
411.79 | 449.68 | 474.96 | 522.49 |
Columns are period end dates